iWallet Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that iWallet Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $10.1K | Jul 26, 2024 |
| FY2022 | Dec 31, 2021 | $69.4K | Jul 7, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Mar 31, 2022 |
| FY2014 | Dec 31, 2014 | $154.6K | Mar 31, 2015 |
| FY2014 | Dec 31, 2013 | $85.8K | Mar 31, 2015 |
| FY2012 | Jun 30, 2012 | $0 | Oct 11, 2012 |
| FY2012 | Jun 30, 2011 | $0 | Oct 11, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $10.1K | Jul 26, 2024 |
| FY2022 | Dec 31, 2021 | $42.0K | Jul 7, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Mar 31, 2022 |
| FY2014 | Dec 31, 2014 | $32.8K | Mar 31, 2015 |
| FY2014 | Dec 31, 2013 | $22.2K | Mar 31, 2015 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.10M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($108.1K) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($267.9K) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($106.7K) | Jul 26, 2024 |
| FY2022 | Dec 31, 2021 | ($346.8K) | Jul 7, 2023 |
| FY2021 | Dec 31, 2020 | ($70.2K) | Mar 31, 2022 |
| FY2014 | Dec 31, 2014 | ($2.42M) | Mar 31, 2015 |
| FY2014 | Jun 30, 2014 | ($24.3K) | Oct 16, 2014 |
| FY2014 | Dec 31, 2013 | ($226.9K) | Mar 31, 2015 |
| FY2014 | Jun 30, 2013 | ($49.2K) | Oct 16, 2014 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($918.2K) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($65.7K) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($225.5K) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($36.4K) | Jul 26, 2024 |
| FY2022 | Dec 31, 2021 | ($203.8K) | Jul 7, 2023 |
| FY2021 | Dec 31, 2020 | ($10.0K) | Mar 31, 2022 |
| FY2014 | Jun 30, 2014 | ($22.3K) | Oct 16, 2014 |
| FY2014 | Jun 30, 2013 | ($47.9K) | Oct 16, 2014 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $267.0K | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 27, 2026 |
| FY2014 | Dec 31, 2014 | $151.2K | Mar 31, 2015 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Jun 30, 2014 | $886 | Oct 16, 2014 |
| FY2014 | Jun 30, 2013 | $669 | Oct 16, 2014 |
| FY2013 | Jun 30, 2012 | $1.1K | Oct 15, 2013 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($52.7K) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($35.1K) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($21.5K) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($36.6K) | Jul 26, 2024 |
| FY2022 | Dec 31, 2021 | $37.7K | Jul 7, 2023 |
| FY2021 | Dec 31, 2020 | ($8.1K) | Mar 31, 2022 |
| FY2014 | Dec 31, 2014 | ($1.70M) | Mar 31, 2015 |
| FY2014 | Jun 30, 2014 | ($14.5K) | Oct 16, 2014 |
| FY2014 | Dec 31, 2013 | ($30.1K) | Mar 31, 2015 |
| FY2014 | Jun 30, 2013 | ($9.7K) | Oct 16, 2014 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $80.3K | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $2.4K | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $1.6K | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $13.0K | Jul 26, 2024 |
| FY2022 | Dec 31, 2021 | $49.7K | Jul 7, 2023 |
| FY2021 | Dec 31, 2020 | $12.0K | Mar 31, 2022 |
| FY2014 | Dec 31, 2014 | $1.07M | Mar 31, 2015 |
| FY2014 | Dec 31, 2013 | $497.0K | Mar 31, 2015 |
| FY2014 | Jun 30, 2013 | $2.1K | Oct 16, 2014 |
| FY2013 | Jun 30, 2012 | $1.8K | Oct 15, 2013 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $895.8K | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $590.5K | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $515.5K | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $921.6K | Jul 26, 2024 |
| FY2022 | Dec 31, 2021 | $851.5K | Jul 7, 2023 |
| FY2021 | Dec 31, 2020 | $782.0K | Mar 31, 2022 |
| FY2014 | Dec 31, 2014 | $344.1K | Mar 31, 2015 |
| FY2014 | Jun 30, 2014 | $172.4K | Oct 16, 2014 |
| FY2014 | Dec 31, 2013 | $719.8K | Mar 31, 2015 |
| FY2014 | Jun 30, 2013 | $150.2K | Oct 16, 2014 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($815.5K) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($588.0K) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($513.9K) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($908.5K) | Jul 26, 2024 |
| FY2022 | Dec 31, 2021 | ($801.8K) | Jul 7, 2023 |
| FY2021 | Dec 31, 2020 | ($770.0K) | Mar 31, 2022 |
| FY2014 | Dec 31, 2014 | $730.9K | Mar 31, 2015 |
| FY2014 | Jun 30, 2014 | ($177.4K) | Oct 16, 2014 |
| FY2014 | Dec 31, 2013 | ($222.8K) | Mar 31, 2015 |
| FY2014 | Jun 30, 2013 | ($148.1K) | Oct 16, 2014 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.69M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($5.59M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($5.48M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($5.21M) | Jul 26, 2024 |
| FY2022 | Dec 31, 2021 | ($5.11M) | Jul 7, 2023 |
| FY2021 | Dec 31, 2020 | ($4.76M) | Mar 31, 2022 |
| FY2014 | Dec 31, 2014 | ($2.65M) | Mar 31, 2015 |
| FY2014 | Jun 30, 2014 | ($211.2K) | Oct 16, 2014 |
| FY2014 | Dec 31, 2013 | ($222.8K) | Mar 31, 2015 |
| FY2014 | Jun 30, 2013 | ($186.9K) | Oct 16, 2014 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $2.4K | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $1.6K | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $13.0K | Jul 26, 2024 |
| FY2022 | Dec 31, 2021 | $49.7K | Jul 7, 2023 |
| FY2021 | Dec 31, 2020 | $12.0K | Mar 31, 2022 |
| FY2021 | Dec 31, 2019 | $20.1K | Mar 31, 2022 |
| FY2014 | Jun 30, 2013 | $2.1K | Oct 16, 2014 |
| FY2013 | Jun 30, 2012 | $1.8K | Oct 15, 2013 |
| FY2012 | Jun 30, 2011 | $6.1K | Oct 11, 2012 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Jul 26, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Jul 7, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 106.42M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | 77.82M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | 72.82M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | 52.82M | Jul 26, 2024 |
| FY2022 | Dec 31, 2021 | 52.82M | Jul 7, 2023 |
| FY2021 | Dec 31, 2020 | 37.82M | Mar 31, 2022 |
| FY2014 | Sep 30, 2014 | 9.04M | Mar 31, 2015 |